| 1418 |
National Cancer Institute |
Html |
en |
Cancer-Related Post-traumatic Stress (PDQ®)–Patient Version |
Shock, fear, helplessness, or horror can be felt by cancer patients at any time and lead to cancer-related post-traumatic stress. Learn about the causes and ways doctors can help manage these symptoms of distress in this expert-reviewed summary. |
| cancer treatment | 0.338437 |
| life-threatening stress | 0.303648 |
| natural disasters | 0.295492 |
| PDQ cancer information | 0.517368 |
| upsetting event | 0.305231 |
| clinical trial search | 0.288109 |
| certain triggers | 0.298605 |
| stressful events | 0.297941 |
| clinical trials | 0.416557 |
| cancer information summary | 0.420357 |
| clinical trial | 0.342943 |
| breast cancer prevention | 0.304611 |
| PDQ summaries | 0.31577 |
| patients | 0.413744 |
| cancer patients | 0.39239 |
| latest published information | 0.297252 |
| childhood cancer survivors | 0.334732 |
| cancer-related PTS | 0.301933 |
| NCI’s PDQ | 0.315928 |
| NCI PDQ cancer | 0.384736 |
| cancer survivors | 0.382895 |
| violent personal attack | 0.28851 |
| cancer-related post-traumatic stress | 0.771546 |
| Breast cancer survivors | 0.324986 |
|
| treatment | 0.388516 |
| post-traumatic stress disorder | 0.44428 |
| cancer prevention | 0.308777 |
| cancer experience | 0.306174 |
| anxiety disorders | 0.288817 |
| Cancer Information Service | 0.325795 |
| PDQ Supportive | 0.310148 |
| treatment clinical trials | 0.303343 |
| National Cancer Institute | 0.448327 |
| post-traumatic stress symptoms | 0.498161 |
| PDQ documents | 0.307297 |
| early symptoms | 0.28734 |
| Palliative Care Editorial | 0.346292 |
| new treatment | 0.299459 |
| possible cancer recurrence | 0.324764 |
| PDQ database | 0.313308 |
| Cancer Care page | 0.31311 |
| Care Editorial Board | 0.347322 |
| PDQ summary | 0.393635 |
| PTSD | 0.349898 |
| PTSD). | 0.290236 |
| cancer clinical trials | 0.330243 |
| cancer information summaries | 0.334057 |
| comprehensive cancer information | 0.334182 |
|
CLICK HERE |
| 1469 |
National Cancer Institute |
Html |
en |
Adult Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult central nervous system tumors. |
| type anaplastic astrocytomas | 0.549962 |
| 5-year analysis | 0.459034 |
| rapid immunohistochemical analysis | 0.458442 |
| mutations aids diagnosis | 0.4781 |
| adjuvant temozolomide | 0.53303 |
| BRAF genetic alterations | 0.471994 |
| pontine gliomas | 0.467631 |
| concurrent radiation therapy | 0.474706 |
| MGMT promoter methylation | 0.572789 |
| Radiation Therapy Oncology | 0.484458 |
| oligodendroglial tumors | 0.468432 |
| adult high-grade glioma | 0.464776 |
| Nervous System Tumors | 0.717497 |
| Astrocytic Tumors Treatment | 0.922097 |
| diffuse astrocytomas | 0.480334 |
| prognostic factor | 0.47815 |
| patients | 0.62456 |
| Primary Central Nervous | 0.835704 |
| Tumor Type section | 0.826321 |
| low-grade gliomas | 0.476475 |
| randomized trials | 0.48238 |
| anaplastic gliomas | 0.467716 |
| Treatment Option Overview | 0.469049 |
| standard systemic chemotherapy | 0.485413 |
|
| mutant tumors | 0.500547 |
| malignant gliomas | 0.567609 |
| radiation therapy | 0.833741 |
| standard chemotherapy agent | 0.48857 |
| Lancet Oncol | 0.46722 |
| glioblastoma patients | 0.504986 |
| Radiation Therapy section | 0.489765 |
| deep-seated tumors | 0.489355 |
| Glioblastomas treatment section | 0.511285 |
| diffuse gliomas | 0.494198 |
| CNS tumors | 0.489107 |
| strong prognostic factor | 0.47196 |
| primary malignant glioma | 0.474955 |
| DNA repair enzyme | 0.549791 |
| standard local treatment | 0.596897 |
| Low-grade tumors | 0.493795 |
| oral agent temozolomide | 0.522443 |
| pilocytic astrocytomas | 0.562223 |
| particular glioma subtypes | 0.489447 |
| newly diagnosed glioblastoma | 0.602836 |
| activating point mutation | 0.473461 |
| Tumors Treatment section | 0.972163 |
| mutant-specific IDH1 antibody | 0.464835 |
| potential diagnostic utility | 0.459778 |
|
CLICK HERE |
| 1491 |
National Cancer Institute |
Html |
en |
Laryngeal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of laryngeal cancer. |
| Elective neck radiation | 0.612858 |
| locally advanced head | 0.629434 |
| radiation therapy-based treatment | 0.65069 |
| randomized controlled trials | 0.580539 |
| Engl J Med | 0.592068 |
| advanced laryngeal cancer | 0.614525 |
| radiation therapy. | 0.583072 |
| Laryngeal Cancer Study | 0.614831 |
| laryngeal cancer | 0.719655 |
| Int J Radiat | 0.605237 |
| randomized study | 0.574463 |
| Radiation Therapy Oncology | 0.613999 |
| neck cancer patients | 0.594571 |
| Radiat Oncol Biol | 0.689017 |
| induction chemotherapy group | 0.591432 |
| patients | 0.718736 |
| initial radiation | 0.58218 |
| standard treatment options | 0.574341 |
| lymph nodes | 0.592104 |
| early-stage larynx cancer | 0.642059 |
| radiation therapy | 0.991511 |
| beam radiation therapy | 0.610314 |
| et al. | 0.672465 |
| concomitant chemotherapy | 0.657903 |
|
| larynx cancer | 0.643614 |
| Affairs Laryngeal Cancer | 0.575648 |
| radiation failures | 0.582504 |
| altered fractionation radiation | 0.602814 |
| intensity-modulated radiation therapy | 0.607841 |
| laryngeal cancers | 0.598434 |
| Concurrent radiation therapy | 0.626365 |
| advanced larynx cancer | 0.579933 |
| radiation field | 0.584791 |
| high local control | 0.57619 |
| definitive radiation therapy | 0.62584 |
| local control | 0.651065 |
| external-beam radiation therapy | 0.622106 |
| early-stage laryngeal cancer | 0.582781 |
| Oncol Biol Phys | 0.693462 |
| lymph node involvement | 0.5855 |
| particle-beam radiation therapy | 0.628769 |
| neck cancer | 0.66828 |
| lymph node | 0.614894 |
| treatment options | 0.588529 |
| local progression-free survival | 0.574463 |
| induction chemotherapy | 0.734401 |
| Cancer Study Group | 0.595423 |
| squamous cell carcinoma | 0.619401 |
|
CLICK HERE |
| 1755 |
National Cancer Institute |
Html |
en |
Genetic Testing for Hereditary Cancer Syndromes |
A fact sheet about genetic testing for inherited cancer risk. Includes types of tests, who should consider testing, and how to understand test results. |
| negative test result | 0.400337 |
| health care provider | 0.502328 |
| genetic mutation | 0.416497 |
| family member | 0.418619 |
| harmful genetic mutation | 0.411753 |
| cancer-predisposing mutation | 0.409751 |
| hereditary cancer disorders | 0.398762 |
| hereditary cancer syndromes | 0.681889 |
| cancer risk condition | 0.40678 |
| health care providers | 0.394471 |
| hereditary cancer syndrome | 0.621674 |
| family members | 0.522464 |
| test results | 0.569131 |
| major hereditary cancer | 0.393709 |
| possible cancer risk | 0.406537 |
| certain hereditary cancer | 0.433421 |
| cancer types | 0.481189 |
| DTC genetic tests | 0.42978 |
| person | 0.492341 |
| Genetic Information Nondiscrimination | 0.390123 |
| genetic tests | 0.554486 |
| specific genetic change | 0.3911 |
| specific cancer type | 0.391368 |
| genetic counselor | 0.453074 |
| male breast cancer | 0.389105 |
|
| DTC genetic testing | 0.513411 |
| genetic counseling | 0.415519 |
| disease-related genetic mutation | 0.41195 |
| family medical history | 0.39883 |
| positive test result | 0.403147 |
| common inherited cancer | 0.408932 |
| particular genetic test | 0.407943 |
| inherited genetic variants | 0.392436 |
| genetic information | 0.399804 |
| health care | 0.626411 |
| genetic test results | 0.557316 |
| genetic change | 0.403267 |
| at-home genetic testing | 0.430532 |
| prenatal genetic test | 0.402782 |
| genetic mutations | 0.44962 |
| breast cancer | 0.417779 |
| Hereditary breast cancer | 0.406679 |
| people | 0.398079 |
| health care decisions | 0.427407 |
| genetic testing | 0.952895 |
| cancer risk | 0.555583 |
| hereditary cancer | 0.711991 |
| cancer | 0.86681 |
| information | 0.408541 |
|
CLICK HERE |
| 1792 |
National Cancer Institute |
Html |
es |
Náuseas y vómitos relacionados con el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las náuseas y vómitos como complicaciones del cáncer o su tratamiento. Se plantean abordajes de tratamiento de las náuseas y vómitos. |
| radioterapia nombre | 0.366149 |
| Dexametasona Corticosteroides | 0.345517 |
| palonosetrón antagonistas | 0.420992 |
| siguientes tipos | 0.357417 |
| siguientes estrategias | 0.348254 |
| único signo | 0.33198 |
| causa náuseas | 0.753796 |
| National Cancer Institute | 0.339057 |
| determinados medicamentos | 0.5578 |
| siguientes riesgos | 0.330997 |
| quimioterapia nombre | 0.555099 |
| PDQ Acupuntura | 0.392476 |
| Instituto Nacional | 0.371538 |
|
| siguientes problemas | 0.372583 |
| siguientes factores | 0.44966 |
| Physician Data Query | 0.449355 |
| Lorazepam Benzodiazepinas | 0.337793 |
| vómitos tardÃos | 0.949937 |
| siguientes caracterÃsticas | 0.461706 |
| determinadas situaciones | 0.34995 |
| fosaprepitant antagonistas | 0.342662 |
| prometazina fenotiacinas | 0.421253 |
| PDQ Náuseas | 0.567745 |
| medicamento tipo | 0.522815 |
| flujo sanguÃneo escaso | 0.412994 |
| haloperidol butirofenonas | 0.346571 |
|
CLICK HERE |
| 1896 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de páncreas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de páncreas. |
| estadio lV | 0.425648 |
| pequeñas incisiones | 0.367032 |
| aguja fina | 0.488715 |
| siguientes procedimientos | 0.412593 |
| Estadio IA | 0.426998 |
| estadio iv | 0.507764 |
| siguientes aspectos | 0.382876 |
| EcografÃa abdominal | 0.386812 |
| estadio ii | 0.546166 |
| células endocrinas | 0.43128 |
| causa ictericia | 0.369929 |
| estadios ia | 0.357173 |
| siguientes tipos | 0.356896 |
| Estadio IIA | 0.42546 |
| rayos x | 0.367548 |
| enlace drugs approved | 0.5669 |
| melanoma familiar atÃpico | 0.436475 |
| ondas sonoras | 0.371814 |
| cercanos.ampliar cáncer | 0.946814 |
| tumores neuroendocrinos | 0.380539 |
| National Cancer Institute | 0.355543 |
| estadio lB | 0.430806 |
| tejidos cercanos.ampliar cáncer | 0.74829 |
|
| endocrina múltiple tipo | 0.4367 |
| Instituto Nacional | 0.397986 |
| estadios iia | 0.360412 |
| PDQ Tratamiento | 0.883614 |
| presente sumario | 0.428926 |
| oculto detrás | 0.371225 |
| antecedentes familiares | 0.366146 |
| ColangiopancreatografÃa retrógrada | 0.374947 |
| Elabora hormonas | 0.377934 |
| estadio llA | 0.424706 |
| explorador tep | 0.376314 |
| PancreatectomÃa distal | 0.35778 |
| Physician Data Query | 0.499092 |
| Pancreatic Cancer | 0.442415 |
| enzimas pancreáticas | 0.350126 |
| estadio iii | 0.513007 |
| CirugÃa paliativa | 0.414657 |
| antÃgeno carcinoembrionario | 0.380177 |
| von hippel-lindau | 0.376964 |
| ovario hereditario | 0.376013 |
| linfáticos cercanos.ampliar cáncer | 0.783386 |
| siguientes pruebas | 0.38409 |
|
CLICK HERE |
| 1969 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de tejido blando en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma de tejido blando en adultos. |
| estadio lV | 0.482165 |
| siguientes procedimientos | 0.954883 |
| estadio iv | 0.615433 |
| siguientes elementos | 0.511302 |
| Neurofibromatosis tipo | 0.50222 |
| von recklinghausen | 0.491269 |
| estadios ia | 0.468147 |
| vÃa oral | 0.457153 |
| estadio il | 0.488391 |
| rayos x | 0.474452 |
| único tratamiento | 0.566108 |
| estadio ib | 0.532006 |
| menor cantidad | 0.562912 |
| estadio ia | 0.530637 |
| carcinoma nevoide | 0.493219 |
| National Cancer Institute | 0.451467 |
| siguientes riesgos | 0.443955 |
| Instituto Nacional | 0.590522 |
|
| PDQ Tratamiento | 0.505529 |
| alta potencia | 0.472015 |
| estadio iia | 0.534137 |
| presente sección | 0.449331 |
| tumor haces estrechos | 0.590695 |
| Drugs Approved | 0.457515 |
| partes distantes | 0.468081 |
| Physician Data Query | 0.588152 |
| Soft Tissue Sarcoma | 0.634121 |
| radioterapia externa causa | 0.549798 |
| adultos causa efectos | 0.535671 |
| área enteras | 0.486295 |
| siguientes enlaces | 0.454055 |
| siguientes pruebas | 0.644136 |
| siguientes sumarios | 0.574908 |
| siguientes estadios | 0.500903 |
| siguientes trastornos | 0.524918 |
|
CLICK HERE |
| 2973 |
National Cancer Institute |
Video |
en |
Make Sure You Have What It Takes |
Ready to quit smoking? Make sure you have what it takes. Visit teen.smokefree.gov. |
| 02 | 0.414634 |
| ElixirMediaProd | 0.414568 |
| CDC | 0.732439 |
| QuitSmokingCom | 0.418054 |
| Sperm | 0.414461 |
| Famous People | 0.497717 |
| body | 0.415775 |
| Anti Smoking Commercial | 0.594002 |
| Disease Control | 0.79595 |
| Michael | 0.432529 |
| List | 0.414915 |
| Belhus | 0.420781 |
| Story | 0.414456 |
| Ellie | 0.41667 |
| Smokers | 0.569726 |
| Asthma Attack | 0.474832 |
| Duration | 0.939681 |
| Home Alchemy | 0.475983 |
| Hollywood | 0.417592 |
| mutation | 0.414755 |
| Smoking Advice | 0.525781 |
| Men | 0.414403 |
| Unattractive Things | 0.479984 |
| basement | 0.414589 |
|
| Smoking Timeline | 0.544895 |
| Centers | 0.483728 |
| NHS Smokefree | 0.484439 |
| Allen Carr | 0.481427 |
| Unkle Adams | 0.494687 |
| Losers Game | 0.480152 |
| air | 0.41576 |
| Aadarsh Sharma | 0.493771 |
| Videos | 0.414563 |
| Prevention | 0.483581 |
| Chicken Egg | 0.47424 |
| Great Ads | 0.480844 |
| smoking | 0.667373 |
| Smoking PSA | 0.536443 |
| views | 0.800457 |
| Terrifying | 0.418131 |
| CDC Tips | 0.549794 |
| James | 0.414466 |
| Domonic Smith | 0.486979 |
| Quit Smoking | 0.543911 |
| COPD patient | 0.483677 |
| Olly | 0.42117 |
| Planet Nibiru | 0.480348 |
| Doritos Commercial Compilation | 0.548737 |
|
CLICK HERE |
| 4389 |
National Cancer Institute |
Html |
en |
Sunlight |
Exposure to UV radiation from the sun, sunlamps, and tanning booths causes early aging and skin damage that can lead to skin cancer. Find information, including tips, on how to protect your skin. |
| skin cancer | 0.670141 |
| sun visors | 0.456822 |
| shades | 0.330644 |
| early aging | 0.476035 |
| dark skin | 0.458278 |
| sources | 0.329654 |
| skin damage | 0.480277 |
| wide brim | 0.466856 |
| windshields | 0.391235 |
| mid-morning | 0.329734 |
| long pants | 0.452301 |
| skin | 0.754109 |
| SPF | 0.373931 |
| ice | 0.356895 |
| UPF | 0.341366 |
| clouds | 0.329163 |
| skin tones | 0.597399 |
| tips | 0.329364 |
| Wear sunglasses | 0.448638 |
| sun protection factor | 0.555629 |
| dark fabrics | 0.445529 |
| light skin tone | 0.592307 |
| hat | 0.32822 |
|
| pavement | 0.327954 |
| mind | 0.357411 |
| late afternoon | 0.469796 |
| light clothing | 0.439637 |
| Exposure | 0.331467 |
| sunscreen products | 0.456996 |
| windows | 0.357118 |
| neck | 0.328307 |
| people | 0.384721 |
| water | 0.356986 |
| UV radiation | 0.940101 |
| sand | 0.362057 |
| sunlight | 0.380409 |
| ultraviolet protection factor | 0.576115 |
| snow | 0.359149 |
| booths | 0.335732 |
| parts | 0.327951 |
| ages | 0.329914 |
| sunlamps | 0.332236 |
| time | 0.329824 |
| beds | 0.330757 |
| rays | 0.330102 |
|
CLICK HERE |
| 15801 |
National Cancer Institute |
Html |
null |
Recommendations of the Blue Ribbon Panel |
Blue Ribbon Panel Report supporting materials include detailed reports from the BRP's seven working groups and a summary report on the public idea submission site. |
|
|
CLICK HERE |